Article
Cardiac & Cardiovascular Systems
Morten Malmborg, Michelle D. S. Schmiegelow, Thomas Gerds, Morten Schou, Caroline Kistorp, Christian Torp-Pedersen, Gunnar Gislason
Summary: This study demonstrates that primary prevention with statins can reduce the risk of cardiovascular events or death in low-risk patients with T2D, with the greatest benefit seen in elderly patients and those with high adherence to statin treatment.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Article
Immunology
Janine M. Trevillyan, Anthony Dart, Eldho Paul, Matthias Cavassini, Jan Fehr, Cornelia Staehelin, Elizabeth M. Dewar, Jennifer F. Hoy, Alexandra Calmy
Summary: Prescribing statins at a lower threshold than guidelines in PLHIV did not lead to improvements in CIMT but was associated with significant adverse events.
Article
Pharmacology & Pharmacy
Jean Michell Santoyo, Jose Antonio Noguera, Francisco Aviles, Trinidad Hernandez-Caselles, Catalina de Paco-Matallana, Juan Luis Delgado, Santiago Cuevas, M. Teresa Llinas, Isabel Hernandez
Summary: This study aimed to assess the effects of pravastatin on the generation of circulating extracellular vesicles in women at high risk of term preeclampsia. The results showed that pravastatin can reduce the levels of cell-derived membrane vesicles in the circulation of high-risk preeclampsia patients, which may help reduce the characteristics of endothelial dysfunction, inflammation, and other features of the disease.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
David J. T. Campbell, Chad Mitchell, Brenda Hemmelgarn, Marcello Tonelli, Peter Faris, Jianguo Zhang, Ross T. Tsuyuki, Jane Fletcher, Flora Au, Scott Klarenbach, Derek Exner, Braden J. Manns
Summary: This study tested whether providing free high-value medications to low-income older adults at high cardiovascular risk would improve clinical outcomes. However, the results showed that although medication adherence improved, providing free medications did not improve clinical outcomes or reduce healthcare costs.
Article
Health Care Sciences & Services
Ashish Sarraju, Gabriela Spencer-Bonilla, Sukyung Chung, Sofia Gomez, Jiang Li, Paul Heidenreich, Latha Palaniappan, Fatima Rodriguez
Summary: This retrospective cohort study examined statin treatment patterns and incident ASCVD among older adults aged 65-79 for primary prevention. It found that patients over 75 years old were less likely to receive moderate- or high-intensity statin prescriptions, and had a higher risk of incident ASCVD compared to younger counterparts. Further research is needed to understand the reasons for age-based differences in statin use and ASCVD risk among older adults.
JOURNAL OF GENERAL INTERNAL MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Jackie Bosch, Eva M. Lonn, Hyejung Jung, Jun Zhu, Lisheng Liu, Patricio Lopez-Jaramillo, Prem Pais, Denis Xavier, Rafael Diaz, Gilles Dagenais, Antonio Dans, Alvaro Avezum, Leopoldo S. Piegas, Alexander Parkhomenko, Kati Keltai, Matyas Keltai, Karen Sliwa, Claus Held, Ronald J. G. Peters, Basil S. Lewis, Petr Jansky, Khalid Yusoff, Kamlesh Khunti, William D. Toff, Christopher M. Reid, John Varigos, Philip Joseph, Lawrence A. Leiter, Salim Yusuf
Summary: Rosuvastatin significantly reduced major adverse cardiovascular events in participants with intermediate cardiovascular risk compared to placebo. The benefits of rosuvastatin continued to increase during post-trial observation period, while blood pressure lowering did not affect the overall study outcomes.
EUROPEAN HEART JOURNAL
(2021)
Article
Cardiac & Cardiovascular Systems
Jackie Bosch, Eva M. Lonn, Hyejung Jung, Jun Zhu, Lisheng Liu, Patricio Lopez-Jaramillo, Prem Pais, Denis Xavier, Rafael Diaz, Gilles Dagenais, Antonio Dans, Alvaro Avezum, Leopoldo S. Piegas, Alexander Parkhomenko, Kati Keltai, Matyas Keltai, Karen Sliwa, Claus Held, Ronald J. G. Peters, Basil S. Lewis, Petr Jansky, Khalid Yusoff, Kamlesh Khunti, William D. Toff, Christopher M. Reid, John Varigos, Philip Joseph, Lawrence A. Leiter, Salim Yusuf
Summary: Rosuvastatin (10 mg daily) reduced major adverse cardiovascular events by 24% compared to placebo in participants at intermediate cardiovascular risk. The benefits of rosuvastatin continued to accrue for at least 3 years after cessation of treatment, indicating a legacy effect.
EUROPEAN HEART JOURNAL
(2021)
Article
Cardiac & Cardiovascular Systems
Chandini Raina MacIntyre, Abrar Ahmad Chughtai, Arpita Das, Bayzidur Rahman, Aye M. Moa, Chieh H. Gan, Timothy C. Tan
Summary: The study found a significantly higher rate of laboratory-confirmed influenza among statin users who were not vaccinated. However, there was no significant difference in influenza vaccine effectiveness between statin users and non-users after vaccination. Statin users had a significantly higher risk of influenza, suggesting that they should be vaccinated against influenza.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2021)
Review
Cardiac & Cardiovascular Systems
Mahmoud Al Rifai, Roger S. Blumenthal, Neil J. Stone, Richard S. Scho, Carl Edward Orringer, Erin D. Michos, Paul A. Heidenreich, Lynne Braun, Kim K. Birtcher, Sidney C. Smith, Vijay Nambi, Scott Grundy, Salim S. Virani
Summary: This review compares the cholesterol guidelines of two major American organizations and reviews the evidence base used to generate recommendations focusing on 4 themes. The different conclusions reached by the two organizations on key issues are discussed.
PROGRESS IN CARDIOVASCULAR DISEASES
(2021)
Article
Public, Environmental & Occupational Health
Danielle Marie Muscat, Erin Cvejic, Katy Bell, Jenna Smith, Georgina May Morris, Jesse Jansen, Rae Thomas, Carissa Bonner, Jenny Doust, Kirsten McCaffery
Summary: This study aimed to explore the impact of health literacy on psychosocial and behavioural outcomes for people who were not at high risk of cardiovascular disease receiving a hypothetical blood pressure reading of 135/85 mmHg. The study found that participants with inadequate health literacy perceived the blood pressure reading to be less serious and reported less motivation for healthy eating and exercise, but were more willing to accept medication. Participants with inadequate health literacy also perceived fewer negative impacts on aspects of life and work, but reported more negative emotion and negative illness perceptions.
PREVENTIVE MEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, Hisayuki Katsuyama
Summary: Randomized controlled trials have shown that reducing LDL-C with statins significantly decreases the risk of developing cardiovascular disease (CVD). However, a considerable number of patients still have residual CVD risk despite statin therapy, particularly in the high-dose statin arms. Elevated TG levels, reduced HDL-C, obesity/insulin resistance, and diabetes are important metabolic factors associated with statin residual CVD risk. Lipoprotein (a), remnant lipoproteins, MDA-LDL, and Sd-LDL play key roles in atherosclerosis and could provide new targets for reducing CVD events in patients receiving statins.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cardiac & Cardiovascular Systems
Antonio J. Vallejo-Vaz, Sarah Bray, Guillermo Villa, Julia Brandts, Gaia Kiru, Jennifer Murphy, Maciej Banach, Stefano De Servi, Dan Gaita, Ioanna Gouni-Berthold, G. Kees Hovingh, Jacek J. Jozwiak, J. Wouter Jukema, Robert Gabor Kiss, Serge Kownator, Helle K. Iversen, Vincent Maher, Luis Masana, Alexander Parkhomenko, Andre Peeters, Piers Clifford, Katarina Raslova, Peter Siostrzonek, Stefano Romeo, Dimitrios Tousoulis, Charalambos Vlachopoulos, Michal Vrablik, Alberico L. Catapano, Neil R. Poulter, Kausik K. Ray
Summary: In patients with atherosclerotic cardiovascular disease (ASCVD), achieving European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) LDL-C goals may result in an additional 2% absolute risk reduction (ARR) over 10 years compared to the American College of Cardiology/American Heart Association (ACC/AHA) approach.
CARDIOVASCULAR DRUGS AND THERAPY
(2023)
Review
Immunology
Kathleen Fitch, Evelynne S. Fulda, Steven K. Grinspoon
Summary: This review focuses on the increased risk of cardiovascular disease (CVD) among people with HIV (PWH) and the potential of statins to mitigate this risk. It discusses the effectiveness of statins in primary CVD prevention in individuals without HIV and highlights the limited data on primary prevention among PWH. The ongoing REPRIEVE trial will provide valuable information on the effects of pitavastatin calcium as a primary prevention strategy for major adverse cardiovascular events in PWH on antiretroviral therapy (ART).
CURRENT OPINION IN HIV AND AIDS
(2022)
Article
Nutrition & Dietetics
Xiaoqing Xu, Wei Wei, Wenbo Jiang, Qingrao Song, Yunyan Chen, Ying Li, Yashuang Zhao, Hongru Sun, Xue Yang
Summary: This study examined the association between folate intake and CVD mortality and all-cause mortality. The results showed that moderate folate intake was associated with a lower risk of CVD mortality and all-cause mortality, while excessive folic acid supplementation may increase the risk of death.
CLINICAL NUTRITION
(2022)
Article
Cardiac & Cardiovascular Systems
Yu-Wen Lin, Chi-Chuan Wang, Chau-Chung Wu, Yih-Ting Hsu, Fang-Ju Lin
Summary: This study found that statin use in elderly individuals without a history of cardiovascular disease can reduce the risk of cardiovascular events and mortality.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2023)
